A Prospective Study of the Incidence of Myasthenia Gravis in the East Midlands of England.


Journal

Neuroepidemiology
ISSN: 1423-0208
Titre abrégé: Neuroepidemiology
Pays: Switzerland
ID NLM: 8218700

Informations de publication

Date de publication:
2019
Historique:
received: 12 03 2019
accepted: 07 04 2019
pubmed: 9 5 2019
medline: 26 6 2020
entrez: 9 5 2019
Statut: ppublish

Résumé

A number of worldwide studies have highlighted a rising incidence of myasthenia gravis (MG) over the past few decades. This is largely due to an increase in numbers in older patients. To establish whether this was a consistent finding in the United Kingdom, we conducted a large, 4-year prospective cohort study of all known patients with new-onset MG in the East Midlands of the United Kingdom. Between 2014 and 2018, all 120 patients with a new diagnosis of MG who were residing in the East Midlands were enrolled. Median age at disease onset was 63 years (78% aged over 50 years) and most patients (57%) were male. The average annual incidence rate (IR) was 17.6/1,000,000 (95% CI 10.7-28.6). IRs remained stable between 2014 and 2018 except for rising IRs in patients over 65 years of age (p value for trend, <0.001). Twenty years after the last comprehensive prospective incidence survey of MG in the east of England, we have demonstrated a rising incidence. The greatest increases seen were in patients over 65 years. Given the rigorous study methods employed, future replicate prospective studies from the same region will establish whether these rising figures are due to biological factors, independent of improved case ascertainment.

Identifiants

pubmed: 31067543
pii: 000500268
doi: 10.1159/000500268
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

93-99

Informations de copyright

© 2019 S. Karger AG, Basel.

Auteurs

Paul Maddison (P)

Department of Clinical Neurology, University of Nottingham, Queen's Medical Centre, Nottingham, United Kingdom, paul.maddison@nhs.net.

Philip Alexander Ambrose (PA)

Department of Clinical Neurology, University of Nottingham, Queen's Medical Centre, Nottingham, United Kingdom.

Girija Sadalage (G)

Department of Clinical Neurology, University of Nottingham, Queen's Medical Centre, Nottingham, United Kingdom.

Angela Vincent (A)

Nuffield Department of Clinical Neurosciences, University of Oxford, West Wing, John Radcliffe Hospital, Oxford, United Kingdom.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH